Selective Serotonin Reuptake Inhibitors in Pregnancy and Congenital Malformations: Population Based Cohort Study

Overview

Journal BMJ

Specialty General Medicine

Date 2009 Sep 25

PMID 19776103

Citations 91

Authors

Lars Henning Pedersen

Tine Brink Henriksen

Mogens Vestergaard

Jorn Olsen

Bodil Hammer Bech

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations.

Design: Population based cohort study.

Participants: 493 113 children born in Denmark, 1996-2003.

Main Outcome Measure: Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005.

Results: Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low-for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI.

Conclusion: There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.

Citing Articles

Medication use before and during pregnancy in Japan: the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study.

Noda A, Obara T, Shirota M, Ueno F, Matsuzaki F, Hatanaka R Eur J Clin Pharmacol. 2024; 80(8):1171-1180.

PMID: 38630193 PMC: 11226522. DOI: 10.1007/s00228-024-03685-7.

Prevalence of Selective Serotonin Reuptake Inhibitor Use Among Pregnant Women From 2017 to 2020 in King Abdulaziz Medical City, Jeddah, Saudi Arabia: A Retrospective Study.

Hakami A, Ahmad R, Bukhari M, Almalki M, Ahmed M, Alghamdi M Cureus. 2023; 15(10):e47745.

PMID: 38021702 PMC: 10676232. DOI: 10.7759/cureus.47745.

Maternal exposure to SSRIs or SNRIs and the risk of congenital abnormalities in offspring: A systematic review and meta-analysis.

Huang W, Page R, Morris T, Ayres S, Ferdinand A, Sinha S PLoS One. 2023; 18(11):e0294996.

PMID: 38019759 PMC: 10686472. DOI: 10.1371/journal.pone.0294996.

Consensus Panel Recommendations for the Pharmacological Management of Pregnant Women with Depressive Disorders.

Eleftheriou G, Zandonella Callegher R, Butera R, De Santis M, Cavaliere A, Vecchio S Int J Environ Res Public Health. 2023; 20(16).

PMID: 37623151 PMC: 10454549. DOI: 10.3390/ijerph20166565.

Major congenital malformations in offspring of women with chronic diseases-impact of the disease or the treatment?.

Demir L, Mathiesen E, Damm P, Ringholm L AJOG Glob Rep. 2023; 3(1):100153.

PMID: 36655167 PMC: 9841280. DOI: 10.1016/j.xagr.2022.100153.

References

Simon G, Cunningham M, Davis R . Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002; 159(12):2055-61. DOI: 10.1176/appi.ajp.159.12.2055. View

Bar-Oz B, Einarson T, Einarson A, Boskovic R, OBrien L, Malm H . Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther. 2007; 29(5):918-926. DOI: 10.1016/j.clinthera.2007.05.003. View

Bennett H, Einarson A, Taddio A, Koren G, Einarson T . Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004; 103(4):698-709. DOI: 10.1097/01.AOG.0000116689.75396.5f. View

Knudsen L, Olsen J . The Danish Medical Birth Registry. Dan Med Bull. 1998; 45(3):320-3. View

Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen P . Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology. 2006; 17(6):701-4. DOI: 10.1097/01.ede.0000239581.76793.ae. View

Einarson T, Einarson A . Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf. 2005; 14(12):823-7. DOI: 10.1002/pds.1084. View

Chambers C, Johnson K, Dick L, Felix R, Jones K . Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996; 335(14):1010-5. DOI: 10.1056/NEJM199610033351402. View

Alwan S, Reefhuis J, Rasmussen S, Olney R, Friedman J . Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007; 356(26):2684-92. DOI: 10.1056/NEJMoa066584. View

Evans J, Heron J, Francomb H, Oke S, Golding J . Cohort study of depressed mood during pregnancy and after childbirth. BMJ. 2001; 323(7307):257-60. PMC: 35345. DOI: 10.1136/bmj.323.7307.257. View

10.

Louik C, Lin A, Werler M, Hernandez-Diaz S, Mitchell A . First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007; 356(26):2675-83. DOI: 10.1056/NEJMoa067407. View

11.

Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D . First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2006; 80(1):18-27. DOI: 10.1002/bdrb.20099. View

12.

Andersen T, Madsen M, Jorgensen J, Mellemkjoer L, Olsen J . The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46(3):263-8. View

13.

Dolk H . EUROCAT: 25 years of European surveillance of congenital anomalies. Arch Dis Child Fetal Neonatal Ed. 2005; 90(5):F355-8. PMC: 1721939. DOI: 10.1136/adc.2004.062810. View

14.

Ericson A, Kallen B, Wiholm B . Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999; 55(7):503-8. DOI: 10.1007/s002280050664. View

15.

Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E . Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol. 2008; 66(5):695-705. PMC: 2661986. DOI: 10.1111/j.1365-2125.2008.03261.x. View

16.

Malm H, Klaukka T, Neuvonen P . Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005; 106(6):1289-96. DOI: 10.1097/01.AOG.0000187302.61812.53. View

17.

Larsen H, Nielsen G, Bendsen J, Flint C, Olsen J, Sorensen H . Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries. Scand J Public Health. 2003; 31(1):12-6. DOI: 10.1080/14034940210134194. View

18.

Hernan M, Hernandez-Diaz S, Werler M, Mitchell A . Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol. 2002; 155(2):176-84. DOI: 10.1093/aje/155.2.176. View

19.

Kallen B, Olausson P . Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006; 21(3):221-2. DOI: 10.1016/j.reprotox.2005.11.006. View

20.

Knudsen L . The Danish Fertility Database. Dan Med Bull. 1998; 45(2):221-5. View